Triple Immunotherapy Combos Enter The Ovarian Cancer Fight
Immunovaccine’s investigational cancer vaccine combined with an immunomodulator and a checkpoint inhibitor or other similar type of agent could have a synergistic beneficial effect on tumor cells, and lead to triple-drug combinations being evaluated in other cancers.
You may also be interested in...
CEO John Milligan offered few details about Gilead's deal strategy during an investor conference last week, but analysts think internal pressure for a major deal is beginning to equal the external sentiment, including an analyst who sees Incyte as a likely target, but not a quick fix for Gilead's declining HCV drug sales.
In its second cancer deal in two months, Incyte licenses a first-in-class asset expected to offer potential cancer immunotherapy synergy with IDO1 and checkpoint inhibition.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.